SETi Releases Portable Air Purifiers with Violeds Technology for New Coronavirus Disinfection in Early June

Sensor Electronic Technology, Inc. (“SETi”), the World’s first compound semiconductor for UV LED solutions (Violeds) and Seoul Viosys (KOSDAQ: 092190)’ subsidiary, announced that it launches portable air purifiers with Violeds technology, brand “VAC”, to reduce infection from various harmful bacteria including new coronavirus (SARS-CoV-2) in the air. The online sales of the products will be started in both South Korea and the United States in June at first, and SETi will also continue to respond to global corporate customer’s demands and inquiries.

Violeds technology has been proven to sterilize 99.9% of new coronavirus in 30 seconds according to testing results. SETi will lead product promotion to provide consumers with quicker access to sterilization solutions until this urgent situation from the global spread of new coronavirus is stabilized. The company will continue to sell the products in cooperation with potential global partners in the future. In addition, it will expand online sales to Europe and Southest Asia in June along with new portable surface sterilizers, brand named “VSM”.

The portable air purifier VAC with Violeds embedded in the air purification system sterilizes new coronavirus and various harmful bacteria. Conventional air purifiers and air conditioners collect various bacteria or viruses using only filters. Accordingly, since it couldn’t completely filter the virus out, there is a high risk of secondary air infection. However, VAC prevents harmful bacteria growing on the filter and significantly sterilizes them by irradiating the filter using Violeds’ light (photon) immediately after virus capture in the air.

HEPA filter in purification system can filter out in general fine dust and droplets more than 0.3μm but the viruses such as new coronavirus and SARS virus itself as small as 0.1μm after the droplet is dried can pass through the HEPA filter as it is.

Violeds technology provides a wide range of applications for air, water and surface sterilization, skin regeneration, insect trap and effective cultivation for horticulture.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version